First Patient Dosed in ASPENOVA Ph 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer May 12, 2026
First patient dosed in clinical trial of EDV™ (EnGeneIC Dream Vector) therapy in patients with recurrent GBM May 12, 2026
Study initiated to evaluate Pidnarulex (CX-5461) + tislelizumab in pancreatic cancer, colorectal cancer, and melanoma May 12, 2026
DMC recommends halting Ph 3 FLASH2 trial of HyBryt (Synthetic Hypericin) in the treatment of CTCL patients post interim efficacy analysis May 6, 2026
TEADCO Ph 1b/2 basket trial of ODM-212 + SoC initiated in patients with select advanced solid tumors April 28, 2026
Dose expansion in clinical study of spevatamig + chemo for treatment of biliary tract cancer April 28, 2026
ADCE-T02 enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors April 28, 2026
First Pancreatic Cancer Patient in Europe treated with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial April 28, 2026
Ph 3 STAR-121 study of domvanalimab, zimberelimab and chemo vs pembrolizumab + chemo in 1L NSCLC to be discontinued April 28, 2026
First US Site Activated for Ongoing International Ph 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced NSCLC April 21, 2026
Nature Medicine Publishes Results Showing Doubling of the Rate of Survival with Elraglusib + Chemo in 1L Metastatic Pancreatic Ductal Adenocarcinoma April 21, 2026
Positive PDS01ADC Interim Ph 2 Trial Data from Stage 1 of NCI-led Metastatic CRC Trial Published April 21, 2026
